Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Investing Activities: 2015-2024

Historic Cash from Investing Activities for Corvus Pharmaceuticals (CRVS) over the last 10 years, with Dec 2024 value amounting to -$27.5 million.

  • Corvus Pharmaceuticals' Cash from Investing Activities rose 32.70% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.8 million, marking a year-over-year decrease of 4.38%. This contributed to the annual value of -$27.5 million for FY2024, which is 276.85% down from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Cash from Investing Activities of -$27.5 million as of FY2024, which was down 276.85% from $15.5 million recorded in FY2023.
  • Corvus Pharmaceuticals' 5-year Cash from Investing Activities high stood at $44.8 million for FY2020, and its period low was -$27.5 million during FY2024.
  • Over the past 3 years, Corvus Pharmaceuticals' median Cash from Investing Activities value was -$23.3 million (recorded in 2022), while the average stood at -$11.7 million.
  • Per our database at Business Quant, Corvus Pharmaceuticals' Cash from Investing Activities surged by 1,275.39% in 2020 and then plummeted by 276.85% in 2024.
  • Yearly analysis of 5 years shows Corvus Pharmaceuticals' Cash from Investing Activities stood at $44.8 million in 2020, then slumped by 51.84% to $21.6 million in 2021, then tumbled by 207.96% to -$23.3 million in 2022, then surged by 166.77% to $15.5 million in 2023, then slumped by 276.85% to -$27.5 million in 2024.